PATHS: Pragmatic Assessment and Treatment for the Health System

Sponsor
IRCCS San Camillo, Venezia, Italy (Other)
Overall Status
Recruiting
CT.gov ID
NCT05809401
Collaborator
IRCCS San Raffaele (Other), Istituto Universitario di Studi Superiori Pavia (Other)
330
3
2
68.6
110
1.6

Study Details

Study Description

Brief Summary

The project goal is to promote a feasible and effective approach to communicative disorders in neurological and psychiatric populations, focused on the pragmatics of language. Pragmatics allows speakers to use and interpret language in context and to engage in successful communication. Pragmatic language disorder is widespread in clinical conditions and causes reduced social interactions and lower quality of life for both patients and their family. Yet it is seldom considered in assessment and rehabilitation.

Condition or Disease Intervention/Treatment Phase
  • Behavioral: Pragmatic Rehabilitation
  • Behavioral: Neuropsychological Rehabilitation
N/A

Detailed Description

The project aims at developing a comprehensive approach for the assessment and treatment of pragmatic impairment in neurological disease. It consists of three Work Packages:

  • The aim of WP1 is to develop a short test of pragmatic abilities. 200 healthy participants will be enrolled for this WP, and the same test will be administered to 40 patients with right hemisphere damage, 40 with traumatic brain injury, and 50 with Schizophrenia.

  • The aim of WP2 is to test the efficacy of a novel treatment for pragmatic disorder. 32 patients will be enrolled (16 for each patient group) and allocated (via Randomized Control Trial) to a standard treatment or to a novel treatment for pragmatic disorders. Only RHD and TBI will take part to this WP.

  • The aim of WP3 is to better clarify the neural correlates of pragmatic abilities. All patients will undergo an high density EEG recording session, and their brain activity will be correlated with performance on neuropsychological tests and on pragmatic impairment. The RHD and TBI patients enrolled for WP2 will undergo a session of hd-EEG also at the end of rehabilitation to monitor brain changes after treatment.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
330 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
Single (Participant)
Primary Purpose:
Treatment
Official Title:
"Assessment and Treatment of Communicative Pragmatic Abilities in Neurological and Psychiatric Disorders: Feasibility and Clinical Efficacy (PATHS)"
Actual Study Start Date :
Nov 13, 2019
Anticipated Primary Completion Date :
Jul 31, 2025
Anticipated Study Completion Date :
Jul 31, 2025

Arms and Interventions

Arm Intervention/Treatment
Experimental: PRAGMACOM

An experimental treatment for pragmatic disorders characterized by activities that focus on conversational rules and on understanding figurative language. The treatment is already tested on Schizophrenic patients.

Behavioral: Pragmatic Rehabilitation
A series of behavioral activities to improve specific pragmatic abilities in patients
Other Names:
  • Pragmatic language Rehabilitation
  • Active Comparator: Standard Neuropsychological Treatment

    The standard treatment for neuropsychological disorders is administered to RHD, and TBI patients in the IRCCS San Camillo Hospital, which consists mostly of attentional training.

    Behavioral: Neuropsychological Rehabilitation
    A series of behavioral activities to improve general aspect of cognition, with a specific focus on attentional abilities.
    Other Names:
  • Cognitive Rehabilitation
  • Outcome Measures

    Primary Outcome Measures

    1. Change in APACS-Brief scores (Assessment of Pragmatic Abilities and Cognitive Substrates - Brief). [for healthy participants and all patients only t0 (immediatly after enrollment. For patients selected for WP2, T0 (after enrollment, as baseline) and T1 (after the treatment, that is after 1.5 months on average)]

      A short test on pragmatic abilities. Scores range from 0 to 1. Higher values indicates better score

    Secondary Outcome Measures

    1. Change in EEG (Electroencephalography) activity - ASSR (Auditory Steady State Response) [for healthy participants and all patients only t0 (immediatly after enrollment. For patients selected for WP2, T0 (after enrollment, as baseline) and T1 (after the treatment, that is after 1.5 months on average)]

      EEG activity for ASSR is measured as power change in 40 Hz frequency as compared to baseline (time window from -100 to 0 ms). Score is unbounded. Higher values indicate better score (i.e., higher synchronization)

    2. Change in EEG (Electroencephalography) activity - MMN (Mismatch Negativity) [for healthy participants and all patients only t0 (immediatly after enrollment. For patients selected for WP2, T0 (after enrollment, as baseline) and T1 (after the treatment, that is after 1.5 months on average)]

      EEG activity for MMN is measured as average voltage deflection in 150-250 ms time window (with -100-0 ms as baseline). Score is unbounded. Larger negative values indicated a better score (i.e., larger MMN)

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    18 Years and Older
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    Yes
    Inclusion Criteria:

    Healthy participants

    • no neurological disorder

    • written informed consent Right Hemisphere Damage (RHD)

    • unilateral stroke

    • first stroke

    • no comorbidities with psychiatric disorders

    • written informed consent TBI

    • traumatic brain injury

    • written informed consent

    Schizophrenia:
    • Diagnosis of Schizophrenia

    • written informed consent

    Exclusion Criteria:
    • Important comorbidities that may affect results

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 IRCCS San Raffaele Milano MI Italy
    2 Istituto Universitario di Studi Superiori Pavia Pavia Italy
    3 IRCCS San Camillo Hospital Venice Italy

    Sponsors and Collaborators

    • IRCCS San Camillo, Venezia, Italy
    • IRCCS San Raffaele
    • Istituto Universitario di Studi Superiori Pavia

    Investigators

    • Principal Investigator: Arcara, IRCCS San Camillo Hospital

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    Responsible Party:
    IRCCS San Camillo, Venezia, Italy
    ClinicalTrials.gov Identifier:
    NCT05809401
    Other Study ID Numbers:
    • 2019.10
    First Posted:
    Apr 12, 2023
    Last Update Posted:
    Apr 12, 2023
    Last Verified:
    Mar 1, 2023
    Individual Participant Data (IPD) Sharing Statement:
    No
    Plan to Share IPD:
    No
    Studies a U.S. FDA-regulated Drug Product:
    No
    Studies a U.S. FDA-regulated Device Product:
    No
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of Apr 12, 2023